SAN DIEGO, Lipidio Pharmaceuticals, Inc. (Lipidio), a newly established biopharmaceutical company developing drugs to treat diseases associated with excess body fat, announced today that is has been included in the 2020 class of Cool Companies by Connect with the San Diego Venture Group (SDVG).

Cool Companies is an annual capital program designed to match San Diego’s best technology and life sciences startups ready to raise Series A — with quality venture capital.  The program selects top tier, local entrepreneurs raising institutional funding, and grants them opportunities for direct access to capital providers. The program regularly attracts over 200 VCs to the region annually. Since 2016, Cool Companies have raised over $400M, in just Series A institutional funding.

“Connect is a great springboard for start-ups in San Diego, giving entrepreneurs access to high quality capital, industry-savvy investors, and a world-class network of colleagues working together to make a meaningful impact on San Diego and the larger biotech ecosystem,” said J. Gordon Foulkes, Ph.D., CEO & Director of Lipidio.  “We are pleased to be recognized in this year’s class of Cool Companies and look forward to continued support from Connect as Lipidio advances our lead program, GDD3898, toward the clinic for the treatment of diseases associated with excess body fat.”

About Connect w/ SDVG

Connect is a community nonprofit organization passionate about helping tech and life science entrepreneurs build great companies. Connect serves entrepreneurs throughout their growth journey with a suite of curated programs aimed to help companies grow, gain access to capital, and scale.  The national venture capital community is annually presented with ‘Cool Companies’, San Diego’s top-performing startups, selected neutrally by our elite community of VCs, angel investors, entrepreneurs, executives, market influencers, and community leaders.

About Lipidio Pharmaceuticals

Lipidio Pharmaceuticals is focused on developing drugs to treat diseases associated with excess body fat and its lead program, GDD3898, is being investigated for the treatment of nonalcoholic steatohepatitis (NASH) and Prader Willi syndrome (PWS), an orphan disease, and anti-psychotic drug induced weight gain (AIWG). Lipidio is headquartered in San Diego, CA.

To learn more, please visit https://lipidiopharma.com/.

Contact:

Amy Conrad
Juniper Point
858-366-3243
amy@juniper-point.com